EB-2022

1 - Marsden, C. D., & Parkes, J. D. (1977). Success and problems of long-term levodopa therapy in Parkinson's disease. The Lancet, 309(8007), 345-349.

2 - Nagatsua T, Sawadab M. L-dopa therapy for Parkinson's disease: past, present, and future. Parkinsonism & related disorders. 2009;15 Suppl 1:S3-8. doi: 10.1016/S1353 8020(09)70004-5. PubMed PMID: 19131039.

3 - Shan L, Diaz O, Zhang Y, Ladenheim B, Cadet JL, Chiang YH, Olson L, Hoffer BJ, Backman CM. L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history. Brain Res. 2015;1618:261-9. Epub 2015/06/19. doi: 10.1016/j.brainres.2015.06.005. PubMed PMID: 26086365; PMCID: PMC4710145.

4 - Fisone G, Bezard E. Molecular mechanisms of l-DOPA-induced dyskinesia. International review of neurobiology. 2011;98:95-122. doi: 10.1016/B978-0-12-381328-2.00004-3. PubMed PMID: 21907084.

5 - Buck K, Ferger B. L-DOPA-induced dyskinesia in Parkinson's disease: a drug discovery perspective. Drug discovery today. 2010;15(19-20):867-75. doi: 10.1016/j.drudis.2010.08.014. PubMed PMID: 20801228.

6 - Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nature reviews Neuroscience. 2008;9(9):665-77. doi: 10.1038/nrn2471. PubMed PMID: 18714325.

7 - Lawton, M., Ben-Shlomo, Y., May, M. T., Baig, F., Barber, T. R., Klein, J. C., ... & Hu, M. T. (2018). Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression. Journal of Neurology, Neurosurgery & Psychiatry, 89(12), 1279-1287.

8 - Padhi, P., Worth, C., Zenitsky, G., Jin, H., Sambamurti, K., Anantharam, V., ... & Kanthasamy, A. G. (2022). Mechanistic Insights Into Gut Microbiome Dysbiosis- Mediated Neuroimmune Dysregulation and Protein Misfolding and Clearance in the Pathogenesis of Chronic Neurodegenerative Disorders. Frontiers in Neuroscience, 16.

9 - Lynch, J. P., Goers, L., & Lesser, C. F. (2022). Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics. Trends in Pharmacological Sciences.